Home Interviews Dr Hoffmann presents results from Chordate’s migraine study

Dr Hoffmann presents results from Chordate’s migraine study

9 September, 2022

Dr Hoffmann presents results from Chordate’s migraine study

9 September, 2022

Chordate Medical recently announced subgroups results from the company’s migraine study showing a statistical significant reduction in number of headache days in patients receiving active K.O.S. treatment compared to the subjects receiving the sham treatment. An abstract with the results is presented at the Migraine Trust International Symposium 2022 in London. BioStock took the opportunity to interview Dr Jan Hoffmann, author of the abstract.

Watch the interview with Dr Hoffmann from King’s College London below:

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.